Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Share-based Compensation (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed Share-based Compensation for 3 consecutive years, with $8.3 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 3.78% to $8.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.7 million through Dec 2025, up 10.26% year-over-year, with the annual reading at $37.7 million for FY2025, 10.26% up from the prior year.
  • Share-based Compensation hit $8.3 million in Q4 2025 for Immunocore Holdings, down from $9.8 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $10.0 million in Q2 2025 to a low of $6.6 million in Q3 2024.
  • Historically, Share-based Compensation has averaged $8.7 million across 3 years, with a median of $8.7 million in 2023.
  • Biggest five-year swings in Share-based Compensation: decreased 20.0% in 2024 and later skyrocketed 49.98% in 2025.
  • Year by year, Share-based Compensation stood at $7.2 million in 2023, then rose by 20.53% to $8.7 million in 2024, then fell by 3.78% to $8.3 million in 2025.
  • Business Quant data shows Share-based Compensation for IMCR at $8.3 million in Q4 2025, $9.8 million in Q3 2025, and $10.0 million in Q2 2025.